March 05, 2009

Even More Evidence Of Placebo Effect In Teen Depression Trials

A new study examining the safety of placebo arms in clinical trials of anti-depressants in teens is out in the American Journal of Psychiatry and, while it doesn't directly examine the placebo effect per se, it certainly shows that there is a sizable placebo effect in these trials, that the effect size of anti-depressants is modest and that the suicide attempts that cropped up among placebo arm patients happened after the teens were on an active treatment later in the trial.

The paper is an analysis of data from the TADS Study (Treatment for Adolescents With Depression Study). It was a fairly long term study and involved 439 patients, aged 12 to 17 years, who were either given Prozac, CBT-alone, CBT and Prozac or placebo. After the first 12 weeks of the study, placebo patients either went into active treatment or left the study.

The safety of placebo arms in depression trials among teens and kids has been questioned over possible harms caused by denying kids the wonders of active anti-depressant treatment and over what negative effects being in a placebo arm initially might present for later anti-depressant treatment. This new study sorts out most of these issues and there are several take-aways.

1. Placebo treatment didn't hurt teens, researchers found, so the ethical question of "denying" treatment is addressed.

2. The teens who were in the initial 12-week placebo arm did fairly well. Of kids on placebo-only for 12 weeks, 35 percent responded to their "treatment" while 58 percent of the other groups did (a very common 23 percent effect size for active treatments including CBT).

3. At week 36, the response rate was 82 percent in the initial placebo group and 83 percent in the active treatment groups, which certainly argues for some level of sustained placebo effect ("Patients who responded to placebo generally retained their response," the study authors note.) The remission rate was 48 percent in the initial placebo patients and 59 percent in the active treatment groups, so certainly not much of an argument can be made that offering kids a placebo limits their ability to respond to other treatments. (It also make me wonder, skeptically of course, about the various prevention paradigm claims made for anti-depressants.)

4. Although the authors don't address this point, I think you can reasonably make the case that the placebo effect exists in both kids and adults undergoing various depression treatments (or taking a placebo) and it ought to become a legitimate object of research. Certainly, a study by Arif Khan last year showed an enormous and long-last placebo effect among adults and a recent meta-study in the AJP showed a large placebo effect in a slew of depression trials in kids and teens.

I'm not sure how much money NIMH is getting of the $1.1 billion in stimulus money designed to sort out which medical treatments work best (I'm dubious of how much of this money will actually create jobs but that's a separate issue), and it would make sense for NIMH to allocate some money to funding real world research on the placebo effect in depression treatment. There's too large of a consistent effect out there to not want to understand how large it is and, if possible, what's driving it (beyond psychological suggestion).

5. There were suicide attempts among initial placebo patients, mostly occurring when the patients either moved to active medication or psychotherapy or a combination. The authors note:

"It is important to note that the large majority of suicide attempts among placebo/open patients (80 percent; 12/15) occurred after the period during which they were on the placebo. Thus, depressed adolescents assigned to placebo condition are for the most part able to tolerate the waiting period without significant clinical distress."

6. Anti-depressant true believers among doctors and advocates are simply running out of road when it comes to making the "anti-depressants for kids are awesome!" argument. Given that a WHO study recently lined up with the FDA black box warning on anti-depressants (at least through the age of 18) as well as with the British ban on their use in under-18s in finding an increased risk of suicide among kids and teens using anti-depressants, it's time for the true believers to reassess their arguments and perhaps argue for extreme caution in the use of anti-depressants in kids and teens, at a minimum. (I'm making no argument here about young adults and adults.)

What's more, the obvious placebo effect apparent in these trials hardly argues in favor of casual anti-depressant use either. Perhaps, it's all really an argument for sugar pills painted to look like Prozac.

Posted by Philip Dawdy at March 5, 2009 12:03 AM
StumbleUpon Toolbar del.icio.us Digg it reddit
Comments

It is so good to hear that no children were harmed by using placebo.

The following is an article [partial] about a woman who recovered from a THIRTY [30] year depression while taking a placebo during a clinical trial. Kind of blows the mind!!

http://www.ssristories.com/show.php?item=2055

This article reads: "And by the end of the study, Schonfeld seemed to be yet another person who owed a nearly miraculous recovery to the new generation of antidepressants -- in this case, venlafaxine, better known as Effexor.
But during her final visit to the institute, one of the doctors directing the research sat her down to deliver some disturbing news. "He told me I hadn't been taking a medicine at all. I'd been on a placebo. I was totally shocked."


http://www.motherjones.com/news/feature/2003/11/ma_565_01.html

Is it Prozac? Or Placebo?
New research suggests that the miracles promised by antidepressants may be largely due to the placebo effect. Too bad there's no money to be made in sugar pills.
By Gary Greenberg
November/December 2003 Issue


Janis Schonfeld recalls the events that started her on her recovery from 30 years of depression with snapshot clarity: the newspaper ad she saw in 1997 seeking subjects for an antidepressant study; the chair she was sitting in when she called UCLA's Neuropsychiatric Institute; the window she was looking out of when she first spoke with Michelle Abrams, the research nurse who shepherded her through the trial. She remembers being both nervous and hopeful when she arrived at the institute, and a little uncomfortable when a technician put gel on her head, attached a nylon cap shot through with electrodes, and recorded her brain activity for 45 minutes. But most of all she remembers getting the bottle of her new pills in a brown paper bag from the hospital pharmacy. "I was so excited," she told me. "I couldn't wait to get started on them."
Within a couple of weeks, Schonfeld, then a 46-year-old interior designer, got quickly and dramatically better, able once again to care for herself and her husband and daughter, no longer so convinced of her own worthlessness that she'd consider killing herself. For the next two months, she came back weekly for more interviews and tests and EEGs. And by the end of the study, Schonfeld seemed to be yet another person who owed a nearly miraculous recovery to the new generation of antidepressants -- in this case, venlafaxine, better known as Effexor.
But during her final visit to the institute, one of the doctors directing the research sat her down to deliver some disturbing news. "He told me I hadn't been taking a medicine at all. I'd been on a placebo. I was totally shocked." So was nurse Abrams. Both women knew that half the test subjects were getting placebos and that Schonfeld might be among them. But not only was she feeling better -- she'd even experienced nausea, a side effect commonly associated with Effexor, so they had each assumed that she was in the drug group. Schonfeld was so certain of this that at first she didn't believe the doctor. "I said to him, 'Are you sure? Check those records again.'" But there was no doubt. The brown bag contained nothing but sugar pills. Which didn't mean, he was quick to add, that she was making anything up, but only that her improvement couldn't possibly be due to the pharmacological effects of the pills.

Posted by: Rosie at March 5, 2009 07:43 AM

There was a paper in PLoS Medicine which investigated the difference between AD and placebo for different levels of depression (mild to severe). It was interesting that the AD's performed as poorly for mild as severe; what was more interesting was how the placebo effect was significantly diminished for the severe whereas for mild it is as good as AD. All too often, mild depression is just normal response to life issues. Given time (placebo), it clears up on its own. As you have noted, there is a rush to drug. For severe which is more likely biological in origin and potentially life threatening, waiting for it to clear may not be wise. In this case, treatment of some sort seems to be the thing to do.

Posted by: Tony at March 5, 2009 10:13 AM

I don't know whether to laugh or cry when I see medical professionals assessing the "safety of placebo" with the implicit assumption that of course the "disease" of mental illness is much more dangerous than any psychotropic treatment they might be evaluating. The whole way in which the problem is constructed makes me weep. The most dangerous piece of the puzzle by far is the pyschotropic drug that's being evaluated. That possibility seems to be far off the radar screen of all the "scientists" listed at the heading of this article. Yet evidence everywhere in clinical practice is screaming that this is in fact the case. According to Philip's summary the only worrisome events on placebo were related in some way to active treatment and that's exactly what has been obscured in so many other "placebo arms" of other trials. So often "placebo events" turn out to be nothing of the sort. They are often withdrawal events dressed up as placebo events (because there is no active treatment right at the time of the event -- it was stopped abruptly shortly before). This in turn makes the active arm look more benign than it really is because the number of "events" are closer to the placebo arm (which was really a withdrawal arm). No treatment turns out not really to be no treatment -- it's abruptly stopped treatment. This is what's dangerous -- abrupt withdrawal -- not no treatment as the fearmongers and sickness sellers would have us believe. If you were really comparing active treatment to a true absence of all medicated treatment, especially over time, you would certainly see just how dangerous and ineffective it is.

Posted by: Sara at March 5, 2009 02:52 PM

I agree with Sara. So many of these placebo clinical trial patients are actually in withdrawal from another drug. This skews the trial results in favor of the active drug and against the placebo.

I will always wonder if all these clinical trials among children actually did result in a suicide or two - contrary to what the authorities would have us believe.

I have confirmation, with all the legal papers from Solvay, that a man, with no previous criminal record, who was in a clinical trial for Luvox in 1993 [yes! the drug Eric Harris of Columbine was taking] murdered another person during the clinical trial. This fact was never made known to the public. The man was sentenced to 15 years in prison and upon early release has undoubtedly signed papers of a secret settlement type. So how many children actually committed suicide during the clinical trials? Was this kept a secret also - with a big payment involved?

Posted by: Rosie at March 5, 2009 08:04 PM

SSRIs seem to still be useful in entrenched OCD not responding to cognitive behaviour therapy, or at least the pills may help the CBT get going. A very rare severe more biological depression may benefit too.

But nearly all depressed kids and teens need the right mix of psychotherapy, lifestyle changes like regular bedtime, nutritious natural food, exercise, addressing family and school issues through family therapy, parenting work, stopping bullying etc etc.

The placebo aspect raises the point that to not give a pill denies people the benefit of the placebo effect.

Luckily there is an alternative to antidepressants that does not risk agitation, apathy or dependency reactions. Fish Oil capsules - for which there is evidence of efficacy above placebo and showing people the literature can boost the placebo effect of the omega-3 capsule as well as them getting real benefit. Good for many systems in the body also.

Posted by: Aussie child psychiatrist at March 9, 2009 10:42 PM
Post a comment









Remember personal info?






pic1.jpg

Winter Fundraiser Underway!!!
Patient Blogs. Sites.
Doctor Blogs. Sites.
Activists. News.
Social Networking. Forums.
Science. Big Pharma. Ethics.
Current Affairs
Seattle Stuff
Smoking. Stuff.

Info
About Furious Seasons
Email
Other Articles
ZYPREXA Documents
Alt ZYPREXA Documents Source
Blakemore-Brown Transcript

 Subscribe in a reader

Recent Entries
Winter Fundraiser, An Early Start
Reasons To Be Skeptical Of "Female Viagra" Drug, Big Pharma's Spanish Fly
Medical Marijuana For Autism?
AstraZeneca Whines About Chicago Tribune's Seroquel Coverage
Big Pharma's Sneaky Trick
Researchers Ignore Problems With Meds In Early Deaths, Blame Smoking, No Exercise
Researchers' New Pediatric Bipolar Disorder Symptoms Include Bed Wetting, Nightmares
Fort Hood Shooting: Was Psychiatrist-Shooter Psychotic Or A Terrorist?
Yale Researcher Links Childhood ADHD To Adult Crime, Drug Dealing
Senator Wants Pentagon To Account For Troop Anti-Depressant Use, Suicide Link
British Government To Limit Antipsychotic Use For Dementia
Child Psychiatrists Behaving Badly With Children
Utah Settles Zyprexa Claims For $24 Million
Psychiatrist Got $490,000 Pimping For Seroquel, Engaged In Wide Off-Label Use
Why Auto Insurance And Health Insurance Aren't The Same, Mr. President
Recent Comments

Aussie child psychiatrist on Even More Evidence Of Placebo Effect In Teen Depression Trials

Rosie on Even More Evidence Of Placebo Effect In Teen Depression Trials

Sara on Even More Evidence Of Placebo Effect In Teen Depression Trials

Tony on Even More Evidence Of Placebo Effect In Teen Depression Trials

Rosie on Even More Evidence Of Placebo Effect In Teen Depression Trials

Archives
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
Resources
Mental Health America
National Alliance on Mental Illness
Depression and Bipolar Support Alliance
National Institute of Mental Health
McMan Web
Search


Powered by
Movable Type 3.2